database > company
Icagen
Biotech Specialty Pharma
4222 Emperor Blvd, Suite 350
Durham, NC 27703 USA
phone:(919) 941-5206
fax:(919) 941-0813
Symbol ICGN
Exchange NASDAQ
Founded 1992
Employees 58
          www.icagen.com
Research Sector Biotech Specialty Pharma
Summary Description
Small molecule drugs that modulate ion channel targets
Management
P. Kay Wagoner, Ph.D., President, Chief Executive Officer and Director; Richard D. Katz, M.D., Executive Vice President, Finance and Corporate Development, Chief Financial Officer; Seth V. Hetherington, M.D., Senior Vice President, Clinical and Regulatory Affairs; Douglas S. Krafte, Ph.D., Vice President - Biology and Scientific Affairs; Gregory C. Rigdon, Ph.D., Vice President, New Product Development
Ownership
Financials Mkt Cap :22
* numbers in thousands
 
Keywords
kappaopioid, receptor agonists, tetrodotoxin, resistant sodium channels, sensory neurons.


Comment | Printable Version | Modify profile Mar. 01, 2010

Description
Icagen is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that modulate ion channel targets. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads.
Products / Services
Name:ICA-105665
Indication: Epilepsy and Pain
Phase: Phase I
Technology / Differentiation
Icagen's technology platform underlies the efficient discovery of all of Icagen's compounds currently in research or development. All of Icagen's compounds work by targeting ion channels. Over the past few years, discoveries related to the molecular structure of channels have advanced our understanding of how ion channels work. This new information has facilitated Icagen's drug discovery efforts.
Market / Customers
Icagen's goal is to become a fully-integrated biopharmaceutical company and a leader in the discovery, development and commercialization of novel small molecule drugs that modulate ion channel targets and address disease areas with significant unmet medical need and commercial potential.


2010-03-12-517